San Diego-dependent Viking Therapeutics marked by itself as a serious competitor in the weight loss drug marketplace in February immediately after revealing promising data from the mid-stage trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when specified as a weekly injection As well as in March